Tempus AI Reports 83% Revenue Growth, Nears Adjusted EBITDA Breakeven in 2025; Details Major Acquisitions and Strategic Partnerships

summarizeSummary

Tempus AI's annual report for fiscal year 2025 reveals a period of aggressive strategic expansion and significant financial improvement. The company achieved substantial revenue growth, driven by its Diagnostics and Data & Applications segments, and dramatically reduced its net and adjusted EBITDA losses, signaling a strong trajectory towards profitability. Key strategic moves include multiple acquisitions that expand its footprint in hereditary testing, digital pathology, and AI-powered clinical trial matching. Furthermore, Tempus AI secured major multi-year collaborations with pharmaceutical giants like AstraZeneca and GlaxoSmithKline, validating its AI-driven platform and providing significant future revenue streams. The company also bolstered its liquidity through a $750 million convertible notes offering and an at-the-market equity program. While facing ongoing patent litigation and a government investigation, the overall picture is one of robust growth and strategic execution in the rapidly evolving precision medicine and AI healthcare sectors.

check_boxKey Events

• Strong Financial Performance

  Total net revenue surged 83% to $1.27 billion in 2025 from $693.4 million in 2024. Net loss significantly decreased to $(245.0) million from $(705.8) million, and Adjusted EBITDA improved to $(7.4) million from $(104.7) million, indicating strong operational leverage and a path towards profitability.

• Strategic Acquisitions Expand Platform

  In 2025, Tempus AI completed several key acquisitions: Ambry Genetics Corporation (hereditary cancer screening) for $375.0 million cash and 4.84 million Class A shares, Paige.AI, Inc. (digital pathology AI) for $3.0 million cash and 1.26 million Class A shares, and Deep 6 AI, Inc. (AI-powered clinical trial matching) for $4.3 million cash and $13.1 million in Class A stock. These acquisitions significantly broaden the company's product offerings and data assets.

• Major Collaborations and Capital Raises

  The company entered into a strategic collaboration with AstraZeneca and Pathos for oncology AI model development, involving a $200 million data license fee to Tempus. Existing collaborations with AstraZeneca (minimum $220M commitment) and GlaxoSmithKline (minimum $180M commitment) were highlighted. Tempus also raised $750.0 million through convertible senior notes and $195.5 million (net) from an at-the-market equity offering, with $300.0 million remaining available.

• Ongoing Legal and Regulatory Challenges

  Tempus AI is involved in patent infringement litigation with Guardant Health concerning liquid biopsy technology, with both companies filing counterclaims. The company also received a Civil Investigative Demand from the U.S. Attorney's Office regarding compliance with healthcare fraud and abuse laws, and faces class action lawsuits under the Illinois Genetic Information Privacy Act.

auto_awesomeAnalysis

Tempus AI's annual report for fiscal year 2025 reveals a period of aggressive strategic expansion and significant financial improvement. The company achieved substantial revenue growth, driven by its Diagnostics and Data & Applications segments, and dramatically reduced its net and adjusted EBITDA losses, signaling a strong trajectory towards profitability. Key strategic moves include multiple acquisitions that expand its footprint in hereditary testing, digital pathology, and AI-powered clinical trial matching. Furthermore, Tempus AI secured major multi-year collaborations with pharmaceutical giants like AstraZeneca and GlaxoSmithKline, validating its AI-driven platform and providing significant future revenue streams. The company also bolstered its liquidity through a $750 million convertible notes offering and an at-the-market equity program. While facing ongoing patent litigation and a government investigation, the overall picture is one of robust growth and strategic execution in the rapidly evolving precision medicine and AI healthcare sectors.